Patient Profiles, Comorbidities, And Cardiovascular Risk In MASLD And MASH – Dr. Christopher Kasia скачать в хорошем качестве

Patient Profiles, Comorbidities, And Cardiovascular Risk In MASLD And MASH – Dr. Christopher Kasia

In this segment, Dr. Christopher Kasia discusses the MASLD patient profile and how common MASLD comorbidities such as type 2 diabetes, obesity, and hypertension influence disease progression. He highlights the crucial role of identifying advanced fibrosis in MASLD, since this stage greatly increases both liver and cardiovascular risk in MASLD patients. Dr. Kasia also explains why metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are often underdiagnosed in primary care, and why early detection is essential to slow MASH progression. With type 2 diabetes and MASLD closely linked, patients with obesity and multiple cardiometabolic conditions face particularly high risks that require aggressive management of fatty liver disease and related comorbidities. What you’ll get to know in this video: ▶ The connection between fatty liver conditions like MASLD and MASH liver disease ▶ Why type 2 diabetes and MASLD combined accelerate disease progression ▶ How obesity and liver disease increase the likelihood of cardiovascular complications ▶ The importance of MASLD risk stratification in identifying high-risk patients ▶ Why liver health is inseparable from long-term cardiovascular outcomes By addressing comorbidities and applying proper MASLD risk stratification, clinicians can better manage fatty liver disease while reducing cardiovascular mortality. This integrated approach is key for improving overall patient outcomes in MASH and MASLD care. #masld #mash #fattyliverdisease #type2diabetes #liverhealth #obesity